GeoVax Labs Reports 2013 Financial Results and Provides Corporate Update

GV-TH-01 is an open label Phase 1 treatment interruption trial investigating the safety and immunogenicity of the GOVX-B11 vaccine in 9 HIV-infected patients who initiated drug treatment within 18 months of and had stably controlled virus for at least 6 months.

http://ift.tt/1l0oN07